NEW YORK, March 19 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX) today announced that Ivan Gergel, MD, Senior Vice President -
Scientific Affairs and President of the Forest Research Institute has
resigned his position and will leave the Company effective March 31, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
Lawrence Olanoff, MD, PhD, President and Chief Operating Officer of
Forest, stated: "The Board and I wish to thank Ivan Gergel for his ten
years of service at Forest. His contributions are appreciated and have been
especially significant for our CNS products, such as Celexa, Lexapro and
Namenda. We wish him well in his future endeavors."
The Company is currently in the process of identifying a potential
successor. In the interim the Forest Research Institute will continue to be
overseen by Dr. Olanoff.
About Forest Laboratories Inc. and Its Products
Forest Laboratories (http://www.frx.com) is a U.S.-based pharmaceutical
company dedicated to identifying, developing, and delivering products that
make a positive difference in peoples' lives. Forest Laboratories' growing
product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated
for adults for the initial and maintenance treatment of major depressive
disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an
N-methyl D-aspartate (NMDA)-receptor antagonist indicated for the treatment
of moderate to severe Alzheimer's disease; Campral(R)* (acamprosate
calcium), indicated in combination with psychosocial support for the
maintenance of abstinence from alcohol in patients with alcohol dependence
who are abstinent at treatment initiation; and Bystolic(TM) (nebivolol), a
beta-adrenergic receptor blocking agent indicated for the treatment of
hypertension. In addition to our growing product line, Forest also
co-promotes the Daiichi Sankyo, Inc. products Benicar(R)* (olmesartan
medoxomil), an angiotensin receptor blocker; Benicar HCT(R)* (olmesartan
medoxomil-hydrochlorothiazide), an angiotensin receptor blocker and
diuretic combination product; and AZOR(TM)* (amlodipine and olmesartan
medoxomil), a calcium channel blocker and angiotensin receptor blocker
combination product, all indicated for the treatment of hypertension.
*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT
are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a
registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA,
Darmstadt, Germany.
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform act of 1995. These statements involve a number
of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to time in
each of Forest Laboratories' Reports on Form 10-K, Quarterly Reports on
Form 10-Q, and any subsequent SEC filings.
SOURCE Forest Laboratories, Inc.
 back to top
Related links:
http://www.frx.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Charles E. Triano, Vice President, Investor
Relations, Forest Laboratories, Inc., +1-212-224-6714,
Charles.Triano@frx.com
|
